You are here: Industry Insights > Crohn’s disease

News List

AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease Pharmaceutical-Business-Review
December 02, 2021
AbbVie has sought approval from the European Medicines Agency (EMA) for risankizumab (Skyrizi, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), to treat patients who are 16 years and above suffering with moderate to...
Risankizumab induces deep remissions in Crohn’s disease trial europeanpharmaceuticalreview
June 04, 2021
Phase III trial data shows more than half of patients with moderate to severe Crohn’s disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year.
Stelara® “a compelling option” for the treatment of Crohn’s disease europeanpharmaceuticalreview
May 25, 2021
Janssen has released abstracts for four studies evaluating Stelara® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC).
Risankizumab trials show higher clinical remission in patients with Crohn’s disease europeanpharmaceuticalreview
January 12, 2021
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn’s disease.
First-in-human trial to study remestemcel-L as Crohn’s disease therapy launched europeanpharmaceuticalreview
October 28, 2020
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
Janssen presents five year data of STELARA in treatment of Crohn’s Disease expresspharma
October 14, 2020
Over half of the patients with moderately to severely active CD who were randomised to subcutaneous ustekinumab every eight weeks and continued to receive this dosage in the LTE study maintained clinical response and remission through five years of ...
AstraZeneca Recovers Global Rights to brazikumab from Allergan americanpharmaceuticalreview
May 14, 2020
AstraZeneca has completed a previously communicated agreement to recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan.
EC approves subcutaneous formulation of Entyvio as maintenance therapy in ulcerative colitis or Croh pharmaceutical-business-review
May 13, 2020
Takeda Pharmaceutical announced that the European Commission has granted a Marketing Authorization for the subcutaneous (SC) formulation of Entyvio (vedolizumab).
EC approves Alofisel for complex perianal fistulae in Crohn’s disease europeanpharmaceuticalreview
April 04, 2018
The EC has approved Alofisel for the treatment of complex perianal fistulae in adult patients with nonactive/mildly active luminal Crohn’s disease…
RedHill Biopharma Announces Expected Timeline for DSMB Meeting and Provides Update on Enrollment in b3cnewswire
July 13, 2017
RedHill Biopharma Ltd. announced that the second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn’s disease (the MAP US study) is expected to convene in late July 2017 and will assess the safety and effi

Previous page 1 2 Next page